Jude Eteneneng Enoh

Dr. Jude Eteneneng Enoh

Walter Sisulu University, Mthatha, South Africa
+1
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2016 in Diabetes Research - Open Journal
Verified
Journal Article
Open access
FTFominyam Boris Tangi
Fominyam Boris Tangi
EFEric Bertrand Fokam
Eric Bertrand Fokam
NLNjunda Anna Longdoh
Njunda Anna Longdoh
JEJude Eteneneng Enoh
Jude Eteneneng Enoh
Background: Intestinal parasites are an important cause of morbidity and mortality and a public health problem especially in tropical developing countries including Cameroon. The two main types of intestinal parasites are helminths and protozoa which are important causes of infections in immunocompromised individuals. Diabetes Mellitus (DM) is a metabolic non-communicabledisease in which a person has high blood glucose. DM is an increasing problem in our community today and diabetics have been reported to be immunocompromised. The purpose of this study was to determine the prevalence and type of intestinal parasites in DM patients living in Buea and Limbe municipalities. Methods: This hospital based cross sectional study involved a total 150 diabetic patients and 85 non-diabetic individuals which served as control group. Questionnaires were administered to the Diabetic patients only. Fresh stool specimens were collected and processed using Direct Microscopy, Formalin-Ether Concentration, Stoll’s technique and Modified Ziehl Nielsen staining techniques. Data was analyzed using Microsoft Office Excel 2013 and Statistical Packagefor Social Sciences (SPSS) version 20. Results: The overall prevalence of intestinal parasites among diabetics was 10%. The parasitesdetected in diabetics included Entamoebahistolytica 10(6.7%), Blastocystishominis 4(2.7%) Ascarislumbricoides 1(0.67%), Hookworm 1(0.67%) and Cryptosporidium parvum 1(0.67%). An overall prevalence of 23.5% of intestinal parasites was observed in the control group with detected parasites Entamoebahistolytica 18(21.2%), Ascarislumbricoides 2(2.4%), and Blastocystishominis 1(1.2%). The prevalence in both groups (10% vs. 23.5%, p=0.0052) were statistically significantly different. DM status was significantly associated with the prevalence of intestinal parasites or acquiring intestinal parasitic infection (OR: 0.36 Confidence Interval (CI)=0.17-0.75; p=0.0051)). Conclusion: The prevalence of intestinal parasites in diabetics is 10%. The most prevalent type of intestinal parasite in diabetics is Entamoebahistolytica which is same with non-diabetics. The more types of intestinal parasites in diabetics and along with the detection of C. parvum indicates a weakened immune system in diabetics. A protective association exists between Diabetes mellitus and Intestinal Parasitic Infections (IPIs). Diabetic patients should be screened routinely for intestinal parasites especially protozoans and treated for their overall well-being.

1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
JEJude Eteneneng Enoh
Jude Eteneneng Enoh
FCFrederick Nchang Cho
Frederick Nchang Cho
FMF. Pascal T Manfo
F. Pascal T Manfo
SASimon Eyongabane Ako
Simon Eyongabane Ako
EAEric Achidi Akum
Eric Achidi Akum
Hepatotoxicity is historically the 3rd most common reason for drug withdrawal and toxicity‐related discontinuation of treatment. This study was aimed at determining the incidence and the onset of hepatotoxicity and at evaluating the relationship of some risk factors for hepatotoxicity among Human Immunodeficiency Virus‐ (HIV‐) positive, tuberculosis (TB), and HIV/TB patients on treatment. This was a prospective follow‐up study involving 125 participants from the HIV/AIDS and TB treatment centres in three hospitals in Fako Division of Cameroon. These TB and HIV patients were initiated on RHEZ (R = Rifampicin, H = Isoniazid, E = Ethambutol, and P = Pyrazinamide) and TELE (efavirenz/tenofovir/lamivudine), respectively, and followed up for 12 weeks between September 2018 and November 2019. The levels of liver enzymes (transaminases, gamma‐glutamyltransferase, alkaline phosphatase, and unconjugated/total bilirubin) were measured spectrophotometrically using serum. The Chi‐squared (χ2) test was used to assess the association between risk factors and hepatotoxicity, while the Kaplan‐Meier survival analysis with the log‐rank test was used to determine the occurrence of hepatotoxicity in the different groups. We followed the general study population for a total person time of 6580 person‐days, with an incidence rate and cumulative incidence of 8 cases per 1000 person‐days (53/6580 person‐days) and 42.4% (53/125), respectively (95% confidence interval), recorded after 12 weeks of follow‐up of all the participants. The onset of hepatotoxicity in the total study population was statistically significant (χ2 = 9.5334; p = 0.022979; CI = 95%), with the majority observed at week eight of follow‐up. Also, the incidence rate and cumulative incidence of hepatotoxicity with respect to HIV/AIDS, TB, and HIV/TB patients, respectively, at 95% confidence interval were: 8 cases per 1000 person‐days (32/3843 person‐days) and 32/76 (42.1%), 6 cases per 1000 person‐days (12/1932 person‐days) and 12/32 (37.5%), and 11 cases per 1000 person‐days (9/805 person‐days) and 9/17 (52.9%). This study shows that the incidence rate and cumulative incidence of hepatotoxicity in HIV/AIDS, TB, and HIV/TB patients on treatment were high in Fako Division, Cameroon. Also, it is very important to check these patients’ liver function especially within the first 12 weeks of treatment.

1 January 2019 in Biomedical and Biotechnology Research Journal
Verified
Journal Article
Open access
PDF file
BPBenjamin David THUMAMO POKAM
Benjamin David THUMAMO POKAM
PGPrisca W Guemdjom
Prisca W Guemdjom
DYD Yeboah-Manu
D Yeboah-Manu
EWElroy P Weledji
Elroy P Weledji
JEJude Eteneneng Enoh
Jude Eteneneng Enoh
AAAnneE Asuquo
AnneE Asuquo
Bovine tuberculosis (BTB), caused by Mycobacterium bovis(M. bovis); a member of the Mycobacterium tuberculosis complex (MTBC), is a well-known zoonotic disease, which affects mainly cattle. Control programs have either nearly or completely eliminated this disease from domesticated animals in many developed countries. Its persistence in developing countries results from interactions between people, livestock transhumance, and wildlife. In addition, deficiencies in preventive and/or control measures, poor sanitation, veterinary and slaughterhouse services, and lack of political measures have been blamed. The proportion of human TB cases caused by M. bovis is most likely underestimated since tests to distinguish between MTBC are seldom performed. Molecular techniques, especially spoligotyping, have helped to link human and animal transmission. Several challenges in the control of M. bovis TB in Africa have been identified, and its eradication efforts require a holistic approach. This review explores the challenges in the control efforts of BTB in Africa, as well as the impact of the genotyping evolution and distribution of M. bovis in the continent and strategies to improve its control.

27 December 2024 in Biomed
Verified
Journal Article
Open access
PDF file
JEJude Eteneneng Enoh
Jude Eteneneng Enoh
RARoland Tiagha Akah
Roland Tiagha Akah
BNBenedicta Ngwenchi Nkeh-Chungag
Benedicta Ngwenchi Nkeh-Chungag
Background: Cardiometabolic risk factors such as hypertension, overweight, and obesity have become increasingly common among African students who tend to become more sedentary in urban environments. This systematic review aimed to determine and identify major risk factors of cardiometabolic disease prevalence reported among African university students. Methods: The protocol was registered with PROSPERO (registration no.CRD42024553280). A comprehensive literature search was performed using scientific databases from Google Scholar, PubMed, Web of Science, Scopus, ProQuest, and African Journals Online (AJOL). The search was limited to articles published between 2000 and 2024, which reported cardiometabolic diseases/risk factors among African university students. Data were extracted using a standardised form, capturing details on study characteristics (author, year, location, study design), participant demographics (age, sex), prevalence of cardiometabolic diseases, and associated risk factors. Results: A total of thirty-seven studies that met the inclusion criteria, thirty-six cross-sectional and one longitudinal, were included in the study. The prevalence range of the various risk factors identified was 0.6–21.7% (obesity) and 0.28–26.4% (hypertension), 1.7–18.8% (diabetes), 0.5–18.2% (pre-diabetes), 1.9–48.6% (metabolic syndrome), and 1.1% to 57.3% (dyslipidemia). Some common sedentary lifestyles and unhealthy behaviours identified among the students were fast foods (21.3–85.73%), alcohol (3.7–63%), and smoking (1.02–13%). Conclusions: The review’s findings suggest that rapid urbanisation and changes in lifestyle and behaviours are responsible for an increased prevalence of cardiometabolic risk factors in African university students. Targeted health promotion programmes, regular screening, and policy interventions might all go a long way in preventing the predicted increase in the prevalence of cardiovascular and metabolic diseases among this group of young adults in Africa.

1 January 2018 in International Journal of Mycobacteriology
Verified
Journal Article
Open access
PDF file
BPBenjamin David Thumamo Pokam
Benjamin David Thumamo Pokam
JEJude Eteneneng Enoh
Jude Eteneneng Enoh
AEAniekan-AugustaO Eyo
Aniekan-AugustaO Eyo
NUNseO Umoh
NseO Umoh
PGPrisca W Guemdjom
Prisca W Guemdjom
Background: Antituberculosis drugs (ATDs) efficiently combat Mycobacterium tuberculosis either through direct molecular interactions or those of its metabolites. However, a variety of adverse effects have been reported, leading to frequent interruptions of treatment. To investigate the possible metabolic disturbances resulting from antituberculosis (TB) treatment, the uric acid (UA) level of patients on ATDs was measured in the southwest region of Cameroon. Methods: This hospital-based cross-sectional study involved 96 TB patients on ATDs and 32 controls who were neither on ATDs nor any other treatment that could increase UA levels. The hospital records of consenting participants were reviewed for medical history and questionnaires were issued. About 2 ml venous blood was collected and analyzed using spectrophotometers to determine UA levels. Results: Hyperuricemia was observed in 56/96 (58.3%) of the studied group as compared with 4/32 (12.5%) in the control group (P < 0.001). Our results indicated that treatment duration was significantly associated with hyperuricemia (P = 0.0016) while gender (P = 0.1275) was not. Conclusion: Hyperuricemia is associated with ATDs, with treatment duration being a significant factor. The disorder should be closely monitored, especially during the intensive phase of treatment.

1 January 2018 in Journal of HIV & Retro Virus
Verified
Journal Article
Open access
PDF file
SASimon Eyongabane Ako
Simon Eyongabane Ako
LNLongdoh Anna Njunda
Longdoh Anna Njunda
EAEric Achidi Akum
Eric Achidi Akum
PBPokam Thumamo Benjamin
Pokam Thumamo Benjamin
JEJude Eteneneng Enoh
Jude Eteneneng Enoh
JAJulius Clement Assob
Julius Clement Assob
Background: Hematological abnormalities are probably the commonest complications with Human Immuno-deficiency Virus (HIV). Some antiretroviral (ARV) drugs have been documented to have cytopenic effects, in particular when used as a mono-therapy. The use of antiretroviral drugs could positively or negatively affect these parameters, depending on the choice of combination used. Records of transfusion associated with HIV patients during treatment in Cameroon are scarce. Hematological profile is supposed to be properly monitored during treatment with respect to other associated risk factors like duration on Anti-Retroviral Therapy (ART) and adherence to ART, to improve on the care of the patients and prevent further complications like transfusion. Method: A hospital-based descriptive cross-sectional study was conducted from January 2015 to May 2015. A total of 285 HIV-1/AIDS adult patients on Highly Active Antiretroviral Therapy (HAART) for at least 6 months were enrolled in this study. Participants were grouped into four based on, duration on HAART; Group one (6 months-1 year), Group two (>1 year-3 years), Group three (>3 years-5 years) and Group four (>5 years). Venous blood was collected and analysed using an automated hematology analyzer (Hematology analyzer Sysmex KX-21) for the following parameters: hemoglobin, number of platelets, total white blood cells and differential in HIV-1 patients. Results: Of the 285 patients studied, 167 (58.6%) were anemic, among which 52 (18.2%) were from group one; 113 (39.7%) had eosinophilia, among which 33 (11.6%) were from group one; 83 (29.1%) were neutropenic, among which 25 (8.8%) were from group four; 57 (20%) had leucopenia, among which 16 (5.6%) were both from group one and three; 40 (14%) had thrombocytopenia, among which 14 (4.9%) were from group three; 15 (5.3%) had thrombocytosis, among which 6 (2.1%) were from group two; 4 (1.4%) had leukocytosis, among which 2 (0.7%) were from group four; and 3 (1.1%) were neutrophilic. There was a significant statistic difference in hematological disorder among treatment groups (groups one, three and four) only for anemia P<0.05. Among the 285 patients, 22 (7.7%) had been transfused either one or more times during HAART. The prevalence of transfusion with respect to treatment groups were 8 (11%) from group two, followed by 5 (7%) from groups one and three, and lastly 4 (6%) from group four, with a statistically significant association between gender (P<0.001), age (P<0.020) and HAART regimen (P<0.001) with transfusion. Conclusion: There were significant prevalence of anemia, eosinophilia, neutropenia, leucopenia and thrombocytopenia in HIV-1 patients on HAART in the south west region of Cameroon. A close monitoring of hematology abnormalities of these patients on HAART is advised. The transfusion rate after initiation of HAART is common in the south west region of Cameroon, and it is significantly associated with HAART regimen, age and gender.